TFX earnings analysis
What we found in TFX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Teleflex's Q1 2026 earnings report highlights a significant revenue increase of 32.3% year-over-year, totaling $548.3 million, largely driven by the newly acquired VI Business. However, gross margins contracted to 56.1%, declining by 560 basis points, while the diluted EPS of $1.39 exceeded consensus estimates.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Q1 2026 revenue rose to $548.3 million, up 32.3% from $414.3 million in Q1 2025.
- Adjusted EPS Outperforming
- Diluted EPS for Q1 2026 stood at $1.39, above the estimated $1.22.
- Segment Growth in EMEA and Asia
- EMEA revenues up 77.5% to $146.7 million, driven by the VI Business acquisition.
- Restructuring Gains Expected
- The company anticipates annual pre-tax savings of $48M to $52M from its Strategic Divestitures restructuring plan.
- Improvement in Cash Flow
- Net cash from operations improved to $46.7 million, from $27.7 million in the same period last year.
- Significant Cash Settlement Received
- Teleflex received $25 million from a litigation settlement, bolstering financial resources.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Tariff Impact
- Gross margin decreased by 560 bps to 56.1% due to adverse tariff effects and increased costs.
- CEO Transition Uncertainty
- Leadership changes may affect strategic direction and operational stability in the near term.
- Activist Investor Pressure
- Emerging activism from Irenic Capital could instigate strategic changes that disrupt current operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.39
- Gross margin
- 56.1%
- Segment
- Americas: $332.7M
- Segment
- EMEA: $146.7M
- Segment
- Asia: $68.9M
What they said about what is next.
Continued 14.40% to 15.40% revenue growth guidance for full-year 2026.
The filing reads better than the one before it.
What came before.
- 10-K · February 27, 2026
- Teleflex’s 2025 10-K frames the year as a strategic inflection: management completed the June 30, 2025 acquisition of BIOTRONIK’s Vascular Intervention business and on December 9, 2025 entered definitive agreements to…
- 10-Q · July 31, 2025
- Teleflex reported quarterly net revenues of $780.9 million, up 4.2% year-over-year, while gross margin compressed 40 basis points to 55.2%. Management achieved cost reductions (SG&A down $35.5 million) and segment…
- 10-K · February 23, 2023
- Teleflex's 10-K report for 2022 highlights a business focused on enhancing clinical benefits and reducing procedural costs through its robust portfolio of medical technology products. The company continues to invest in…
- 10-Q · July 28, 2022
- Teleflex reported quarterly net revenues of $704.5M, down $9.0M or 1.3% versus the year-ago quarter, with gross profit of $388.8M (55.2% of sales, down 50 bps). Consolidated segment operating profit was $166.5M…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TFX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever